Cigna’s Express Scripts Sues FTC Over Drug Pricing Report

Tuesday, 17 September 2024, 04:23

Cigna’s Express Scripts has initiated a lawsuit against the FTC concerning the recent drug pricing report. This report sheds light on how PBMs impact drug pricing in the U.S., raising concerns about rising costs. The legal action highlights ongoing tensions surrounding pharmaceutical pricing.
LivaRava_Medicine_Default.png
Cigna’s Express Scripts Sues FTC Over Drug Pricing Report

Cigna’s Express Scripts Lawsuit Against FTC

Cigna’s Express Scripts has taken a significant legal step by suing the Federal Trade Commission (FTC) over a recent report that addresses the growing crisis of drug pricing in the United States. The FTC's findings pointed to the pivotal role that Pharmacy Benefit Managers (PBMs) play in the escalating costs of prescription medications.

Impact of PBMs on Drug Prices

The FTC report emphasizes how PBMs may contribute to soaring drug prices, raising alarms among healthcare providers and patients alike. As the case unfolds, it will shine a spotlight on the operational practices of PBMs and their effect on medication affordability.

Legal Implications

This legal action by Express Scripts not only seeks to challenge the FTC’s conclusions but also aims to influence the regulatory landscape surrounding drug pricing practices in the U.S. The outcome may set a precedent for how PBMs operate and are held accountable in the healthcare sector.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe